RNA therapeutics for metabolic disorders.

No abstract is available for this paper.

• Publication year

  2024

• Venue

  Progress in Molecular Biology and Translational Science

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/bs.pmbts.2023.12.014PMID 38359998
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inotersen to Treat Polyneuropathy Associated with Hereditary Transthyretin (hATTR) Amyloidosis.

  2023cited by this paper
• Chemistry, structure and function of approved oligonucleotide therapeutics

  2023cited by this paper
• RNA therapeutics: updates and future potential

  2022cited by this paper
• Vutrisiran: First Approval

  2022cited by this paper
• RNA-based therapeutics: an overview and prospectus

  2022cited by this paper
• The promising novel therapies for familial hypercholesterolemia

  2022cited by this paper
• mRNA-based therapeutics: powerful and versatile tools to combat diseases

  2022cited by this paper
• Translational Pharmacokinetic/Pharmacodynamic Model for mRNA-3927, an Investigational Therapeutic for the Treatment of Propionic Acidemia

  2022cited by this paper
• Advancements in mRNA Encoded Antibodies for Passive Immunotherapy

  2021cited by this paper
• Lumasiran: First Approval

  2021cited by this paper
• Targeting RNA with small molecules: from fundamental principles towards the clinic.

  2021cited by this paper
• The role of mitochondria in Duchenne muscular dystrophy.

  2021cited by this paper
• Oxidative Stress: Pathogenetic Role in Diabetes Mellitus and Its Complications and Therapeutic Approaches to Correction

  2021cited by this paper
• The current landscape of nucleic acid therapeutics

  2021cited by this paper
• Givosiran: A Review in Acute Hepatic Porphyria

  2021cited by this paper
• Antisense technology: an overview and prospectus

  2021cited by this paper
• The Limitless Future of RNA Therapeutics

  2021cited by this paper
• Inclisiran: First Approval

  2021cited by this paper
• Outcomes in Bariatric and Metabolic Surgery: an Updated 5-Year Review

  2020cited by this paper
• Developmental Origins of Metabolic Disease.

  2020cited by this paper
• Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging

  2020cited by this paper
• Therapeutic siRNA: state of the art

  2020cited by this paper
• Volanesorsen: First Global Approval

  2019cited by this paper
• Targeting RNA: A Transformative Therapeutic Strategy

  2019cited by this paper
• Messenger RNA therapy for rare genetic metabolic diseases

  2019cited by this paper
• mRNA: A Novel Avenue to Antibody Therapy?

  2019cited by this paper
• Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.

  2019cited by this paper
• Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application

  2019cited by this paper
• Inotersen: First Global Approval

  2018cited by this paper
• An update on physical health and economic consequences of overweight and obesity.

  2018cited by this paper
• RNA-Targeted Therapeutics.

  2018cited by this paper
• Patisiran: First Global Approval

  2018cited by this paper
• Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way

  2017cited by this paper
• Aptamers as Therapeutics.

  2017cited by this paper
• Natural Nanoparticles: A Particular Matter Inspired by Nature

  2017cited by this paper
• Metabolism disrupting chemicals and metabolic disorders.

  2017cited by this paper
• Health Effects of Overweight and Obesity in 195 Countries over 25 Years.

  2017cited by this paper
• Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs

  2017cited by this paper
• Mitochondrial diseases

  2016cited by this paper
• Diagnosis, treatment, and prevention of gout.

  2014cited by this paper
• mRNA-based therapeutics — developing a new class of drugs

  2014cited by this paper
• Gene therapy on the move

  2013cited by this paper
• Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery

  2013cited by this paper
• Ammonia toxicity to the brain

  2013cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Hybridization of 2'-ribose modified mixed-sequence oligonucleotides: thermodynamic and kinetic studies.

  2001cited by this paper
• Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

  1998cited by this paper
• Urea cycle disorders: diagnosis, pathophysiology, and therapy.

  1996cited by this paper
• Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets.

  1993cited by this paper
• Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

  1978cited by this paper
• Nucleoside phosphorothioates.

  1970cited by this paper
• Synthesis of 2'-O-methyluridine, 2'-O-methylcytidine and their relating compounds.

  1965cited by this paper
• Unstable Ribonucleic Acid Revealed by Pulse Labelling of Escherichia Coli

  1961cited by this paper
• An Unstable Intermediate Carrying Information from Genes to Ribosomes for Protein Synthesis

  1961cited by this paper

• The functionally conserved human lncRNA motif GULF lowers glucose and lipid levels in obese mice

  2025cites this paper